{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:16:13Z","timestamp":1794244573466,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) are prognostic factors in epithelial ovarian cancer (EOC). Their predictive value for platinum-sensitivity and their role in recurrent EOC are unknown. A total of 375 EOC patients were retrospectively analyzed. The correlation between baseline NLR and SII, and platinum-free interval (PFI) according to first line bevacizumab treatment were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Subsequently NLR and SII calculated before second line treatment initiation were evaluated to identify a potential correlation with progression-free survival (PFS) and overall survival (OS) in platinum-sensitive and in platinum-resistant population. In multivariate analysis, NLR\u2009\u2265\u20093 is an independent predictive factor for PFI at 6\u00a0months in the chemotherapy group (OR\u2009=\u20092.77, 95% CI 1.38\u20135.56, <jats:italic>p<\/jats:italic>\u2009=\u20090.004), not in bevacizumab treated patients. After having adjusted for ECOG performance status, histology, ascites, bevacizumab treatment at second line and BRCA status, NLR\u2009\u2265\u20093 and SII\u2009\u2265\u2009730 are significantly associated with worse OS in platinum-sensitive (HR\u2009=\u20092.69, 95% CI 1.60\u20134.53, <jats:italic>p<\/jats:italic>\u2009=\u20090.002; HR\u2009=\u20092.11, 95% CI 1.29\u20133.43, <jats:italic>p<\/jats:italic>\u2009=\u20090.003, respectively), not in platinum-resistant EOC patients. Low NLR is an independent\u00a0predictive factor\u00a0for platinum-sensitivity in patients treated without bevacizumab. NLR and SII are prognostic factors in recurrent platinum-sensitive EOC patients.<\/jats:p>","DOI":"10.1038\/s41598-020-75316-x","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T10:06:00Z","timestamp":1603447560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study"],"prefix":"10.1038","volume":"10","author":[{"given":"Alberto","family":"Farolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zavallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Attademo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gall\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisena","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pigozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Loizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Giorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"75316_CR1","unstructured":"GLOBOCAN https:\/\/gco.iarc.fr\/ consulted on 1st April 2020"},{"key":"75316_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","volume":"80","author":"J Prat","year":"2018","unstructured":"Prat, J., D\u2019Angelo, E. & Espinosa, I. Ovarian carcinomas: At least five different diseases with distinct histological features and molecular genetics. Hum. Pathol. 80, 11\u201327 (2018).","journal-title":"Hum. Pathol."},{"key":"75316_CR3","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3390\/ijms20102569","volume":"20","author":"A Farolfi","year":"2019","unstructured":"Farolfi, A. et al. Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches. Int. J. Mol. Sci. 20, 2569 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"75316_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"75316_CR5","doi-asserted-by":"publisher","first-page":"dju249","DOI":"10.1093\/jnci\/dju249","volume":"106","author":"GE Konecny","year":"2014","unstructured":"Konecny, G. E. et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst. 106, dju249 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"75316_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"75316_CR7","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland, K. C. et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 7, 13587\u201313598 (2016).","journal-title":"Oncotarget."},{"key":"75316_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2018.07.025","volume":"151","author":"MP Pinto","year":"2018","unstructured":"Pinto, M. P. et al. Patient inflammatory status and CD4+\/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol. 151, 10\u201317 (2018).","journal-title":"Gynecol Oncol."},{"key":"75316_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld, T. et al. The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24 (2017).","journal-title":"Front. Oncol."},{"key":"75316_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1084\/jem.20181170","volume":"216","author":"W Lee","year":"2019","unstructured":"Lee, W. et al. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J. Exp. Med. 216, 176\u2013194 (2019).","journal-title":"J. Exp. Med."},{"key":"75316_CR11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/bjc.2013.522","volume":"109","author":"M Santoni","year":"2013","unstructured":"Santoni, M. et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br. J. Cancer. 109, 1755\u20131759 (2013).","journal-title":"Br. J. Cancer."},{"key":"75316_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1245\/s10434-014-4097-4","volume":"22","author":"L Rossi","year":"2015","unstructured":"Rossi, L. et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann. Surg. Oncol. 22, 1377\u20131384 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"75316_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fphar.2016.00376","volume":"7","author":"C Lolli","year":"2016","unstructured":"Lolli, C. et al. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front. Pharmacol. 7, 376 (2016).","journal-title":"Front. Pharmacol."},{"key":"75316_CR14","doi-asserted-by":"publisher","first-page":"33210","DOI":"10.18632\/oncotarget.8901","volume":"7","author":"A Passardi","year":"2016","unstructured":"Passardi, A. et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget. 7, 33210\u201333219 (2016).","journal-title":"Oncotarget."},{"key":"75316_CR15","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 106, dju124 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"75316_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ygyno.2017.02.026","volume":"145","author":"JL Ethier","year":"2017","unstructured":"Ethier, J. L. et al. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol. 145, 584\u2013594 (2017).","journal-title":"Gynecol Oncol."},{"key":"75316_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ygyno.2018.05.004","volume":"150","author":"T Baert","year":"2018","unstructured":"Baert, T. et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol. Oncol. 150, 31\u201337 (2018).","journal-title":"Gynecol. Oncol."},{"key":"75316_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11523-018-0574-1","volume":"13","author":"A Farolfi","year":"2018","unstructured":"Farolfi, A. et al. Inflammatory indexes as prognostic and predictive factors in ovarian cancer treated with chemotherapy alone or together with bevacizumab. A multicenter, retrospective analysis by the MITO group (MITO 24). Target. Oncol. 13, 469\u2013479 (2018).","journal-title":"Target. Oncol."},{"key":"75316_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4143\/crt.2016.282","volume":"49","author":"ES Paik","year":"2017","unstructured":"Paik, E. S. et al. Nomograms predicting platinum sensitivity, progression-free survival, and overall survival using pretreatment complete blood cell counts in epithelial ovarian cancer. Cancer Res. Treat. 49, 635\u2013642 (2017).","journal-title":"Cancer Res. Treat."},{"key":"75316_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.smim.2016.03.018","volume":"28","author":"K Moses","year":"2016","unstructured":"Moses, K. & Brandau, S. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Semin. Immunol. 28, 187\u2013196 (2016).","journal-title":"Semin. Immunol."},{"key":"75316_CR21","doi-asserted-by":"publisher","first-page":"e17475","DOI":"10.1097\/MD.0000000000017475","volume":"98","author":"X Yin","year":"2019","unstructured":"Yin, X., Wu, L., Yang, H. & Yang, H. Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis. Medicine (Baltimore) 98, e17475 (2019).","journal-title":"Medicine (Baltimore)"},{"key":"75316_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"M Friedlander","year":"2011","unstructured":"Friedlander, M. et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21, 771\u2013775 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"75316_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo, N. et al. ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 30, 672\u2013705 (2019).","journal-title":"Ann. Oncol."},{"key":"75316_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"75316_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","volume":"366","author":"RL Stone","year":"2012","unstructured":"Stone, R. L. et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366, 610\u2013618 (2012).","journal-title":"N. Engl. J. Med."},{"key":"75316_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces epithelial-mesenchymal-like transition and promote metastasis. Cancer Cell 20, 576\u2013590 (2011).","journal-title":"Cancer Cell"},{"key":"75316_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","volume":"58","author":"N Leffers","year":"2009","unstructured":"Leffers, N. et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58, 449\u2013459 (2009).","journal-title":"Cancer Immunol. Immunother."},{"key":"75316_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5468\/ogs.2020.63.1.55","volume":"63","author":"D Jeerakornpassawat","year":"2020","unstructured":"Jeerakornpassawat, D. & Suprasert, P. Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy. Obstet. Gynecol. Sci. 63, 55\u201363 (2020).","journal-title":"Obstet. Gynecol. Sci."},{"key":"75316_CR29","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"75316_CR30","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"75316_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.19.02055","volume":"38","author":"A Farolfi","year":"2020","unstructured":"Farolfi, A., Lorusso, D., Pignata, S. & De Giorgi, U. Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing. J. Clin. Oncol. 38, 172\u2013173 (2020).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75316-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75316-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75316-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:51:41Z","timestamp":1670363501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75316-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75316"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75316-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Farolfi reports personal fees and non-financial support from Tesaro, non-financial support from Jansenn-Cilag, non-financial support from Ipsen, personal fees from Astrazeneca, outside the submitted work. Dr. Pignata reports grants and personal fees from roche, grants and personal fees from az, grants and personal fees from MSD, grants and personal fees from Pfizer, personal fees from Tesaro, personal fees from Pharmamar, outside the submitted work. Dr. De Giorgi reports personal fees and non-financial support from Janssen-Cilag, personal fees from Astellas, grants and personal fees from Sanofi, personal fees from Bayer, personal fees and non-financial support from Pfizer, personal fees and non-financial support from BMS, personal fees from Novartis, personal fees and non-financial support from Ipsen, personal fees from MSD, grants and non-financial support from Roche, grants from Astrazeneca, personal fees from Pharmamar, outside the submitted work. Emanuela Scarpi, Filippo Greco, Alice Bergamini, Lucia Longo, Claudia Casanova, Gennaro Cormio, Alessandra Bologna, Michele Orditura, Laura Zavallone, Laura Attademo, Valentina Gall\u00e0, Elisena Franzese, Eva Pigozzi, Vera Loizzi, Giorgio Giorda, Donatella Giardina, Raffaella Cioffi declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18190"}}